Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29265203 | 1.00 | CRBN (0.55) | CRBNDDB1GPR119USP30PDK2 | |
| SCHEMBL22119507 | 0.89 | DDB1 (0.59) | CRBNDDB1GPR119PDK2MAPT | |
| SCHEMBL23173797 | 0.87 | CRBN (0.56) | CRBNDDB1GPR119USP30ALDH1A1 | |
| SCHEMBL30831015 | 0.85 | CRBN (0.54) | CRBNDDB1USP30 | |
| SCHEMBL31201874 | 0.84 | CRBN (0.47) | CRBNDDB1GPR119PDK2MAPT | |
| SCHEMBL27349010 | 0.84 | CRBN (0.47) | CRBNDDB1GPR119PDK2MAPT | |
| SCHEMBL30952388 | 0.84 | DDB1 (0.50) | CRBNDDB1GPR119PDK2MAPT | |
| SCHEMBL30703627 | 0.84 | DDB1 (0.48) | CRBNDDB1GPR119PDK2MAPT | |
| SCHEMBL30257613 | 0.83 | DDB1 (0.52) | CRBNDDB1USP30MAPTALDH1A1 | |
| SCHEMBL25079570 | 0.83 | DDB1 (0.52) | CRBNDDB1USP30MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4438603-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023093845-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | AR, NR5A1, CYP17A1 | CRBN 743/4885DDB1 4432/4885GPR119 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.